KR960704579A - 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin) - Google Patents

옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin)

Info

Publication number
KR960704579A
KR960704579A KR1019960701611A KR19960701611A KR960704579A KR 960704579 A KR960704579 A KR 960704579A KR 1019960701611 A KR1019960701611 A KR 1019960701611A KR 19960701611 A KR19960701611 A KR 19960701611A KR 960704579 A KR960704579 A KR 960704579A
Authority
KR
South Korea
Prior art keywords
lactate
reservoir
mixture
skin
oxybutynin
Prior art date
Application number
KR1019960701611A
Other languages
English (en)
Inventor
은 수 이
타일러 와따나베
로버트 엠. 게일
테리 엘. 불코쓰
Original Assignee
에드워드 엘. 만델
앨자 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에드워드 엘. 만델, 앨자 코포레이션 filed Critical 에드워드 엘. 만델
Publication of KR960704579A publication Critical patent/KR960704579A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

특정 농도로 존재하는 투여될 옥시부티닌의 치료 유효량; 및 모노글리세리드 또는 모노글리세리드의 혼합물, 및 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 투과-촉진 혼합물의 조합으로 이루어지는, 체표면이나 막을 통한 투과에 의해 옥시부티닌을 투여하기 위한 체표면 또는 막에 사용되는 물질의 조성물.

Description

옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer for Oxybutynin)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (47)

  1. (a) 투여될 옥시부티닌의 치료 유효량 및 (b) (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 투과-촉진 혼합물의 조합으로 이루어지는 체표면이나 막을 통한 투과에 의해 옥시부티닌을 투여하기 위한 체표면 또는 막에 작용하는 물질의 조성물.
  2. 제1항에 있어서, 모노글리세리드 또는 모노글리세리드의 혼합물이 조성물의 20중량%를 이루며, 락테이트 에스테르 12중량%를 이루는 것인 조성물.
  3. 제1항에 있어서, 락테이트 에스테르가 라우릴 락테이트인 조성물.
  4. 제1항에 있어서, 락테이트 에스테르가 에틸 락테이트인 조성물.
  5. 제1항에 있어서, 락테이트 에스테르가 미리스틸 락테이트인 조성물.
  6. 제1항에 있어서, 락테이트 에스테르가 세틸 락테이트인 조성물.
  7. 제1항에 있어서, 락테이트 에스테르의 혼합물이 에틸 락테이트 및 라우릴 락테이트인 조성물.
  8. 제3 내지 7항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 조성물.
  9. 제8항에 있어서, 글리세롤 모노라우레이트 및 락테이트 에스테르가 각각 조성물의 20중량% 및 12중량%를 이루는 것인 조성물.
  10. (a) 치료 유효량의 옥시부티닌 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는, 치료 유효 속도에서의 옥시부티닌의 경피 투여용 장치.
  11. (a) 치료 유효량의 옥시부티닌 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 제1저장고; (b) 과량의 투과 촉진 혼합물 및 포화 이하의 옥시부티닌으로 이루어지는 제2저장고; (c) 제1저장고 및 제2저장고 사이의 속도-조절막; (d) 저장고의 피부 반대편 상의 배면; 및 (e) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는, 치료 유효 속도에서의 옥시부티닌의 경피 투여용 장치.
  12. 제10 또는 11항에 있어서, 추가로 유지 수단의 피부 반대편 상의 미세다공성 막으로 이루어지는 것인 장치.
  13. 제10 또는 11항에 있어서, 모노글리세리드 또는 모노글리세리드의 혼합물 20중량% 및 락테이트 에스테르 12중량%로 이루어지는 것인 장치.
  14. 제10 또는 11항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 장치.
  15. 제10 또는 11항에 있어서, 락테이트 에스테르가 라우릴 락테이트인 장치.
  16. 제10 또는 11항에 있어서, 락테이트 에스테르가 에틸 락테이트인 장치.
  17. 제10 또는 11항에 있어서, 락테이트 에스테르가 세틸 또는 미리스틸 락테이트인 장치.
  18. 제10 또는 11항에 있어서, 락테이트 에스테르의 혼합물이 에틸 및 라우릴 락테이트인 장치.
  19. 제10 또는 11항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며, 락테이트 에스테르가 에틸 락테이트 또는 라우릴 락테이트 또는 그의 혼합물인 장치.
  20. 제10 또는 11항에 있어서, 약물이 R-옥시부티닌인 장치.
  21. 제10항에 있어서, 저장고와 피부 사이의 관계를 유지시켜주는 수단이 저장고의 피부 인접면 상의 인-라인(in-line) 접착층으로 이루어지는 것인 장치.
  22. 제11항에 있어서, 저장고와 피부 사이의 관계를 유지시켜주는 수단이 제1저장고의 피부 인접면 상의 인-라인(in-line) 접착층으로 이루어지는 것인 장치.
  23. 제11항에 있어서, 제1저장고 또한 저장고와 피부 사이의 관계를 유지시켜주는 수단으로서 기능하는 접착층인 장치.
  24. 제15 내지 18항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 장치.
  25. 제24항에 있어서, 글리세롤 모노라우레이트 및 락테이트 에스테르가 약물 함유 저장고의 각각 20중량% 및 12중량%로 이루어지는 것인 장치.
  26. (a) (ⅰ) 옥시부티닌 15 내지 30중량%, (ⅱ) 글리세롤 모노라우레이트 15 내지 25중량%, (ⅲ) 라우릴 락테이트 8 내지 25중량%, 및 (ⅳ) 에틸렌 비닐 아세테이트 공중합체 20 내지 62중량%로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는, 치료 유효 속도에서의 옥시부티닌의 경피 투여용 장치.
  27. 제26항에 있어서, 저장고가 추가로 2 내지 30중량%의 가교된 폴리-N-비닐피롤리돈으로 이루어지는 것인 장치.
  28. 제26항에 있어서, 추가로 유지 수단의 피부 반대쪽 표면 상의 미세다공성 막으로 이루어지는 것인 장치.
  29. 제26 내지 28항 중 어느 한 항에 있어서, 저장고가 20중량%의 글리세롤 모노라우레이트 및 12중량%의 라우릴 락테이트로 이루어지는 것인 장치.
  30. (a) 옥시부티닌을 치료 유효 속도로 피부 면적에 투여하고, (b (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 투과-촉진 혼합물을 약물에 대한 침투성을 실질적으로 증가시키기에 충분한 속도로 피부 면적에 동시 투여하는 것으로 이루어지는, 옥시부티닌의 경피 투여 방법.
  31. (a) 치료 유효량의 옥시부티닌 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는 경피 약물 전달 장치를 환자의 피부 상에 올려 놓는 단계로 이루어지는 옥시부티닌의 경피 투여 방법.
  32. (a) 치료 유효량의 옥시부티닌 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 제1저장고; (b) 과량의 투과 촉진 혼합물 및 포화 이하의 옥시부티닌으로 이루어지는 제2저장고; (c) 제1저장고 및 제2저장고 사이의 속도-조절막; (d) 저장고의 피부 반대편 상의 배면; 및 (e) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는 경피 약물 전달 장치를 환자의 피부 상에 올려 놓는 단계로 이루어지는 옥시부티닌의 경피 투여 방법.
  33. 제30 내지 32항 중 어느 한 항에 있어서, 장치가 추가로 유지 수단의 피부 반대쪽 표면 상의 미세다공성 막으로 이루어지는 것인 방법.
  34. 제30 내지 32항 중 어느 한 항에 있어서, 20중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 12중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 것인 방법.
  35. 제30 내지 32항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 방법.
  36. 제30 내지 32항 중 어느 한 항에 있어서, 락테이트 에스테르가 라우릴 락테이트인 방법.
  37. 제30 내지 32항 중 어느 한 항에 있어서, 락테이트 에스테르가 에틸 락테이트인 방법.
  38. 제30 내지 32항 중 어느 한 항에 있어서, 락테이트 에스테르가 세틸 또는 미리스틸 락테이트인 방법.
  39. 제30 내지 32항 중 어느 한 항에 있어서, 락테이트 에스테르의 에틸 및 라우릴 락테이트인 방법.
  40. 제30 내지 32항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며, 락테이트 에스테르가 에틸 락테이트 또는 라우릴 락테이트 또는 그의 혼합물인 방법.
  41. 제36 내지 39항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며, 글리세롤 모노라우레이트가 20중량%를 이루고 락테이트 에스테르가 12중량%를 이루어지는 것인 방법.
  42. (a) (ⅰ) 옥시부티닌 15 내지 30중량%, (ⅱ) 글리세롤 모노라우레이트 15 내지 25중량%, (ⅲ) 라우릴 락테이트 8 내지 25중량%, 및 (ⅳ) 에틸렌 비닐 아세테이트 공중합체 20 내지 62중량%로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는 경피 약물 전달 장치를 환자의 피부 상에 올려 놓는 단계로 이루어지는 옥시부티닌의 경피 투여 방법.
  43. 제42항에 있어서, 장치가 추가로 유지 수단의 피부 반대쪽 표면 상의 미세다공성 막으로 이루어지는 것인 방법.
  44. 제42 또는 43항에 있어서, 저장고가 (ⅰ) 옥시부티닌 25중량%, (ⅱ) 글리세롤 모노라우레이트 20중량%, (ⅲ) 라우릴 락테이트 12%, 및 (ⅳ) 에틸렌 비닐 아세테이트 공중합체 43중량%로 이루어지는 것인 방법.
  45. 제42 또는 43항에 있어서, 저장고가 추가로 2 내지 30중량%의 가교된 폴리-N-비닐 피롤리돈으로 이루어지는 것인 방법.
  46. 제42 내지 44항 중 어느 한 항에 있어서, 옥시부티닌이 R-옥시부티닌인 방법.
  47. 제42 내지 44항 중 어느 한 항에 있어서, 옥시부티닌이 S-옥시부티닌인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701611A 1993-09-29 1994-09-29 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin) KR960704579A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12949493A 1993-09-29 1993-09-29
US129,494 1993-09-29
PCT/US1994/011226 WO1995009007A1 (en) 1993-09-29 1994-09-29 Monoglyceride/lactate ester permeation enhancer for oxybutynin

Publications (1)

Publication Number Publication Date
KR960704579A true KR960704579A (ko) 1996-10-09

Family

ID=22440240

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019960701610A KR960704578A (ko) 1993-09-29 1994-09-29 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
KR1019960701611A KR960704579A (ko) 1993-09-29 1994-09-29 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1019960701610A KR960704578A (ko) 1993-09-29 1994-09-29 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)

Country Status (10)

Country Link
US (3) US5750137A (ko)
EP (2) EP0721349A1 (ko)
JP (3) JP3792252B2 (ko)
KR (2) KR960704578A (ko)
AT (1) ATE183926T1 (ko)
AU (2) AU679794B2 (ko)
CA (2) CA2165802A1 (ko)
DE (1) DE69420419T2 (ko)
NZ (2) NZ274711A (ko)
WO (2) WO1995009006A1 (ko)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5919478A (en) * 1993-06-25 1999-07-06 Alza Corporation Incorporating poly-N-vinyl amide in a transdermal system
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
FR2735027B1 (fr) * 1995-06-07 1998-01-09 Alza Corp Compositions de renforcateurs de permeation d'agents a travers la peau, comprenant de l'acetate de lauryle et un monoglyceride
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997024148A1 (en) * 1995-12-29 1997-07-10 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
ATE226816T1 (de) * 1996-07-03 2002-11-15 Alza Corp Vorrichtungen zur arzneistoffabgabe und herstellungsverfahren
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
GB9618964D0 (en) * 1996-09-11 1996-10-23 Tillotts Pharma Ag Oral composition
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
DE29823343U1 (de) * 1998-03-20 1999-07-15 Schwarz Pharma Ag, 40789 Monheim Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
NZ513441A (en) † 1999-02-08 2004-01-30 Alza Corp Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2000064434A1 (fr) * 1999-04-26 2000-11-02 Lead Chemical Co., Ltd. Preparations percutanees contenant de l'oxybutynine
WO2000064528A1 (en) * 1999-04-28 2000-11-02 Situs Corporation Drug delivery system
AU767877B2 (en) * 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
ES2338860T3 (es) * 1999-11-24 2010-05-13 Agile Therapeutics, Inc. Sistema y procedimiento de administracion de anticonceptivos transdermica mejorado.
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
JP2003531157A (ja) 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
CA2440884C (en) * 2001-03-16 2012-05-22 Alza Corporation Transdermal patch for administering fentanyl
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SI1513532T1 (sl) 2002-06-10 2007-08-31 Euro Celtique Sa Sistemi za odstranjevanje priprav za transdermalno oddajanje za preprečevanje zlorabe učinkovin, ki jih vsebujejo
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
DE10251256A1 (de) * 2002-11-04 2004-05-13 Novosis Ag Transdermales Wirkstoffabgabesystem für Oxybutynin
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
DK1684782T3 (en) * 2003-10-03 2015-11-02 Thorn Bioscience Llc PROCEDURE FOR SYNCHRONIZING OVULATION FOR TEMPORARY REGULATED BREEDING WITHOUT BROWN DETECTION
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
US20060004094A1 (en) * 2004-07-02 2006-01-05 Agisim Gary R Composition and method for treating hemorrhoids and/or anorectal disorders
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
EP2216018B1 (en) 2004-10-21 2012-04-04 Durect Corporation Transdermal delivery systems
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007011763A2 (en) * 2005-07-15 2007-01-25 3M Innovative Properties Company Adhesive sheet and methods of use thereof
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
CA2575398C (en) * 2006-02-02 2011-12-20 Omp, Inc. Methods of treating skin to enhance therapeutic treatment thereof
WO2007095147A2 (en) * 2006-02-13 2007-08-23 Aveva Drug Delivery Systems Adhesive preparation comprising sufentanil and methods of using the same
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
KR101583680B1 (ko) * 2007-10-15 2016-01-08 알자 코퍼레이션 펜타닐의 1일-1회 교체 경피 투여
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
ES2661240T3 (es) 2009-04-23 2018-03-28 Jbs United Animal Health Ii Llc Método y composición para sincronizar el momento de inseminación
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9950952B2 (en) 2010-11-30 2018-04-24 Schlumberger Technology Corporation Methods for servicing subterranean wells
US9834719B2 (en) * 2010-11-30 2017-12-05 Schlumberger Technology Corporation Methods for servicing subterranean wells
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
ES2808409T3 (es) 2012-11-28 2021-02-26 United Ah Ii Llc Método para sincronizar el tiempo de inseminación en cerdas primerizas
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
KR20150119468A (ko) 2013-02-28 2015-10-23 더미라, 인코포레이티드 글리코피롤레이트 염
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
RU2016116915A (ru) * 2013-10-01 2017-11-13 Новартис Аг Комбинация
SG11201602596UA (en) 2013-10-03 2016-04-28 Dow Pharmaceutical Sciences Stabilized efinaconazole compositions
EP3071295A4 (en) 2013-11-22 2017-05-31 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2973372A1 (en) 2015-01-09 2016-07-14 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN109803649B (zh) * 2016-10-11 2022-10-21 久光制药株式会社 含有奥昔布宁的透皮吸收制剂
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
JP6582158B1 (ja) * 2017-10-30 2019-09-25 科研製薬株式会社 爪白癬治療用の外用製剤
JP7220473B2 (ja) * 2017-10-30 2023-02-10 帝國製薬株式会社 経皮投与製剤
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3527864A (en) * 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US4116956A (en) * 1968-11-05 1978-09-26 Takeda Chemical Industries, Ltd. Benzodiazepine derivatives
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3987052A (en) * 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3903256A (en) * 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) * 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) * 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4130643A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
US4508726A (en) * 1982-09-16 1985-04-02 The Upjohn Company Treatment of panic disorders with alprazolam
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4710497A (en) * 1983-05-20 1987-12-01 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering physiologically active agents
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4590190A (en) * 1983-07-01 1986-05-20 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4588739A (en) * 1984-03-02 1986-05-13 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4683231A (en) * 1984-03-02 1987-07-28 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4783456A (en) * 1984-03-02 1988-11-08 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4663454A (en) * 1985-04-17 1987-05-05 The Upjohn Company Process to prepare α-chloroalprazolam
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4685913A (en) * 1985-05-24 1987-08-11 Professional Care Products, Inc. External single-use catheter
JPS61293911A (ja) * 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US4666903A (en) * 1985-08-13 1987-05-19 Yale University Novel use of benzodiazepine antagonist
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4863720A (en) * 1986-03-10 1989-09-05 Walter Burghart Pharmaceutical preparation and methods for its production
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4876249A (en) * 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
CH674618A5 (ko) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
JPH0720866B2 (ja) * 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5017575A (en) * 1987-06-09 1991-05-21 Golwyn Daniel H Treatment of immunologically based disorders, specifically Crohn's disease
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4925844A (en) * 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
JP2794022B2 (ja) * 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US4981468A (en) * 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5246949A (en) * 1989-12-06 1993-09-21 Sansho Co., Ltd. Preparation for endermism containing dopamine derivatives
JPH03236317A (ja) * 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
PT100502A (pt) * 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
CA2132865C (en) * 1992-05-13 2003-12-02 Eun S. Lee Transdermal administration of oxybutynin
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer

Also Published As

Publication number Publication date
JP2006117688A (ja) 2006-05-11
KR960704578A (ko) 1996-10-09
CA2165802A1 (en) 1995-04-06
JP3688293B2 (ja) 2005-08-24
EP0721348A1 (en) 1996-07-17
DE69420419D1 (de) 1999-10-07
ATE183926T1 (de) 1999-09-15
JPH09505279A (ja) 1997-05-27
US5686097A (en) 1997-11-11
AU7924994A (en) 1995-04-18
CA2167526A1 (en) 1995-04-06
EP0721348B1 (en) 1999-09-01
NZ274711A (en) 1996-11-26
WO1995009007A1 (en) 1995-04-06
JP3792252B2 (ja) 2006-07-05
AU679793B2 (en) 1997-07-10
AU679794B2 (en) 1997-07-10
WO1995009006A1 (en) 1995-04-06
US5750137A (en) 1998-05-12
NZ275615A (en) 1996-11-26
EP0721349A1 (en) 1996-07-17
DE69420419T2 (de) 1999-12-23
AU7964794A (en) 1995-04-18
US5747065A (en) 1998-05-05
JPH09505278A (ja) 1997-05-27

Similar Documents

Publication Publication Date Title
KR960704579A (ko) 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin)
US5122383A (en) Sorbitan esters as skin permeation enhancers
CA2264687C (en) Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CA1316106C (en) Skin permeation enhancer compositions using glycerol monolaurate
EP0561983B1 (en) Systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers
US4865848A (en) Skin permeation enhancer compositions using sucrose esters
US4900555A (en) Skin permeation enhancer compositions using sucrose esters
US4690683A (en) Transdermal varapamil delivery device
US4940586A (en) Skin permeation enhancer compositions using sucrose esters
US5227169A (en) Sorbitan esters as skin permeation enhancers
GB2165148A (en) Transdermal administration of fentanyl
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
EP0857488A3 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
KR950701516A (ko) 옥시부티닌의 경피 투여(Transdermal Administration of Oxybutynin)
WO1993008841A1 (en) Skin permeation enhancer compositions
AU6476496A (en) Novel formulations for transdermal delivery of pergolide
MX9709162A (es) Composiciones mejoradas de la permeacion en la piel que usan lactilatos de acilo.
US5900250A (en) Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5212199A (en) Sorbitan esters as skin permeation enhancers

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid